STOCK TITAN

Major COSCIENS (CSCI) holder slashes stake from 8.2% to 0.5%

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

PETER PUCCETTI AND PUCCETTI FUNDS MANAGEMENT INC. have sharply reduced their reported stake in COSCIENS Biopharma Inc. to 15,687 common shares, representing about 0.5% of shares outstanding. This follows the sale of all of Puccetti’s indirect equity interest in Goodwood Inc., which managed Goodwood Fund.

Goodwood Fund previously held 241,570 COSCIENS shares that had been reported as beneficially owned by the reporting persons. After the transaction, Puccetti no longer owns or controls Goodwood, Goodwood Fund, or those shares, and a prior joint filing agreement among the parties has been terminated.

The filing confirms Puccetti’s remaining exposure is held indirectly through Puccetti Funds and that the group has ceased to beneficially own more than 5% of COSCIENS common stock, though Puccetti continues to serve as interim CEO and chair of the board.

Positive

  • None.

Negative

  • None.
Current beneficial ownership 15,687 shares COSCIENS common stock beneficially owned by reporting persons as of Closing Date
Current ownership percentage 0.5% of class Percentage of COSCIENS common stock outstanding represented by 15,687 shares
Prior beneficial ownership 257,257 shares COSCIENS common stock previously beneficially owned or controlled by Goodwood / Puccetti entities
Prior ownership percentage 8.2% of class Previous percentage of COSCIENS outstanding common shares held by Goodwood / Puccetti entities
Shares outstanding 3,183,330 shares COSCIENS common shares outstanding as of December 31, 2025, per Form 20-F
Cost of remaining shares $45,171.98 Aggregate amount, including commissions, used by Puccetti Funds to acquire 15,687 shares
Cost of Goodwood Fund shares $1,579,611.92 Aggregate amount, including commissions, used to acquire the 241,570 Goodwood Fund Shares
beneficially own financial
"As of the Closing Date, Peter Puccetti and Puccetti Funds beneficially own an aggregate of 15,687 Shares of Common Stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Joint Filing Agreement regulatory
"the Joint Filing Agreement dated December 19, 2024 (the "Joint Filing Agreement") among Goodwood, Goodwood Fund, and Puccetti Funds"
Sub-Advisory Agreement financial
"Goodwood and Nour are parties to a Sub-Advisory Agreement dated November 11, 2025 (the "Sub-Advisory Agreement")"
A sub-advisory agreement is a contract in which the primary investment manager of a fund or portfolio hires a separate, specialist firm to manage some or all of the assets. For investors this matters because it can change who actually makes trading and strategy decisions, how fees are split, and how performance and risk are handled—similar to a homeowner hiring a specialist contractor who may yield different results than the main builder.
Resolution Agreement financial
"the Issuer entered into a resolution agreement (the "Resolution Agreement") with Goodwood, Goodwood Fund and Puccetti Funds"
Rule 13d-3 regulatory
"do not confer voting power or dispositive power over any securities of the Issuer as those terms are defined in Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
Form 25 regulatory
"the Issuer filed a Form 25 with the U.S. Securities and Exchange Commission in order to effect a voluntary delisting from NASDAQ"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many COSCIENS (CSCI) shares do Peter Puccetti and Puccetti Funds now beneficially own?

They now beneficially own 15,687 COSCIENS common shares, or about 0.5% of the class. These shares are held indirectly through Puccetti Funds Management Inc., following transactions that removed previously reported holdings managed by Goodwood Fund from their beneficial ownership.

How did Peter Puccetti’s beneficial ownership in COSCIENS (CSCI) change in this amendment?

The reported stake fell from roughly 257,257 shares (about 8.2%) to 15,687 shares (about 0.5%). This change reflects the sale of Puccetti’s indirect equity interest in Goodwood Inc., which managed Goodwood Fund, and termination of their prior reporting group.

Why do the reporting persons no longer report Goodwood Fund’s COSCIENS (CSCI) shares?

Puccetti’s company sold all its equity interest in Goodwood Inc. to Nour Private Management. After this sale, Puccetti no longer owns or controls Goodwood or Goodwood Fund, so the 241,570 COSCIENS shares held by Goodwood Fund are no longer beneficially owned by the reporting persons.

What is COSCIENS Biopharma’s (CSCI) total common shares outstanding used in this filing?

The filing references 3,183,330 COSCIENS common shares outstanding as of December 31, 2025. This figure comes from the company’s Form 20-F and is used to calculate that Puccetti’s 15,687 shares represent approximately 0.5% of the outstanding common stock.

What roles does Peter Puccetti currently hold at COSCIENS Biopharma (CSCI)?

He serves as interim Chief Executive Officer and Chairman of the Board. The filing notes he is also a portfolio manager and investment advisor and that his advisory work for Goodwood or potential future work with Nour does not grant him voting or dispositive power over COSCIENS securities.

How much was spent acquiring the COSCIENS (CSCI) shares still owned by the reporting persons?

Approximately $45,171.98, including brokerage commissions, funded the remaining 15,687 shares. These purchases were made with working capital of Puccetti Funds, which may include margin loans, through open-market transactions in COSCIENS common stock.

What did the filing say about COSCIENS (CSCI) delisting and U.S. reporting status?

The company voluntarily delisted from NASDAQ via Form 25 effective September 5, 2025. COSCIENS is exploring ways to terminate or suspend its U.S. Exchange Act reporting obligations and expects to present a related proposal at its June 2025 annual shareholder meeting.





22112H101

(CUSIP Number)
Peter Puccetti
2845 Bristol Circle,
Oakville, A6, L6H 6X5
(416) 203-2022

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
03/01/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Peter Puccetti
Signature:/s/ Peter Puccetti
Name/Title:Peter Puccetti
Date:04/17/2026
Puccetti Funds Management Inc.
Signature:/s/ Peter Puccetti
Name/Title:Peter Puccetti, President
Date:04/17/2026